EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Clinical utility of genomic profiling of AML using paraffin‐embedded bone marrow clots: HM‐SCREEN‐Japan 01

Naoko Hosono iD, SungGi Chi iD, Takahiro Yamauchi iD, Kentaro Fukushima, Hirohiko Shibayama, Seiichiro Katagiri, Akihiko Gotoh, Motoki Eguchi, Takanobu Morishita, Reiki Ogasawara, Takeshi Kondo, Masamitsu Yanada und 19 weitere

Cancer Science · 2023

DOI: 10.1111/cas.15746 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Science, 2023. Verfasst von Naoko Hosono und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematologic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Next‐generation sequencing of AML has identified specific genetic mutations in AML patients. Hematologic Malignancies (HM)‐SCREEN‐Japan 01 is a multicenter study to detect actionable mutations using paraffin‐embedded bone marrow (BM) clot specimens rather than BM fluid in AML patients for whom standard treatment has not been established. The purpose of this study is to evaluate the presence of potentially therapeutic target gene mutations in patients with newly diagnosed unfit AML and relapsed/refractory AML (R/R‐AML) using BM clot specimens. In this study, 188 patients were enrolled and targeted sequencing was undertaken on DNA from 437 genes and RNA from 265 genes. High‐quality DNA and RNA were obtained using BM clot specimens, with genetic alterations successfully detected in 177 patients (97.3%), and fusion transcripts in 41 patients (23.2%). The median turnaround time was 13 days. In the detection of fusion genes, not only common fusion products such as RUNX1 ‐ RUX1T1 and KMT2A rearrangements, but also NUP98 rearrangements and rare fusion genes were observed. Among 177 patients (72 with unfit AML, 105 with R/R‐AML), mutations in KIT and WT1 were independent factors for overall survival (hazard ratio = 12.6 and 8.88, respectively), and patients with high variant allele frequency (≥40%) of TP5 3 mutations had a poor prognosis. As for the detection of actionable mutations, 38% ( n = 69) of patients had useful genetic mutation ( FLT3 ‐ ITD / TKD , IDH1 / 2 , and DNMT3A R822 ) for treatment selection. Comprehensive genomic profiling using paraffin‐embedded BM clot specimens successfully identified leukemic‐associated genes that can be used as therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematologic NeoplasmsHumansBone MarrowPrognosisNucleophosminJapanParaffin EmbeddingMutationRNAGenomics

Stichwörter der Autor:innen

AMLFoundationOne Hemeactionable mutationineligible for standard chemotherapyparaffin-embedded bone marrow clot

Substanzen

NucleophosminRNA

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan.
  • Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Department of Hematology, Tokyo Medical University Hospital, Tokyo, Japan.
  • Division of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
  • Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.

ORCID-Profile: Naoko Hosono, SungGi Chi, Takahiro Yamauchi, Kazuhito Yamamoto, Tsutomu Kobayashi, Junya Kuroda, Makoto Yoshimitsu, Kenji Ishitsuka, Takaaki Ono, Naoto Takahashi, Suguru Fukuhara, Koji Izutsu, Yosuke Minami

Zitieren

APA

Hosono, N., Chi, S., Yamauchi, T., Fukushima, K., Shibayama, H., Katagiri, S., Gotoh, A., Eguchi, M., Morishita, T., Ogasawara, R., Kondo, T., Yanada, M., Yamamoto, K., Kobayashi, T., Kuroda, J., Usuki, K., Utsu, Y., Yoshimitsu, M., Ishitsuka, K., …, & All HM-SCREEN-Japan 01 Investigators (2023). Clinical utility of genomic profiling of AML using paraffin‐embedded bone marrow clots: HM‐SCREEN‐Japan 01. Cancer Science. https://doi.org/10.1111/cas.15746

Vancouver

Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, et al. Clinical utility of genomic profiling of AML using paraffin‐embedded bone marrow clots: HM‐SCREEN‐Japan 01. Cancer Science. 2023. doi:10.1111/cas.15746

BibTeX
@article{Hosono2023,
  author = {Hosono, Naoko and Chi, SungGi and Yamauchi, Takahiro and Fukushima, Kentaro and Shibayama, Hirohiko and Katagiri, Seiichiro and Gotoh, Akihiko and Eguchi, Motoki and Morishita, Takanobu and Ogasawara, Reiki and Kondo, Takeshi and Yanada, Masamitsu and Yamamoto, Kazuhito and Kobayashi, Tsutomu and Kuroda, Junya and Usuki, Kensuke and Utsu, Yoshikazu and Yoshimitsu, Makoto and Ishitsuka, Kenji and Ono, Takaaki and Takahashi, Naoto and Iyama, Satoshi and Kojima, Kensuke and Nakamura, Yukinori and Fukuhara, Suguru and Izutsu, Koji and Abutani, Hikaru and Yamauchi, Nobuhiko and Yuda, Junichiro and Minami, Yosuke and All HM-SCREEN-Japan 01 Investigators, All HM-SCREEN-Japan 01 Investigators},
  title = {Clinical utility of genomic profiling of AML using paraffin‐embedded bone marrow clots: HM‐SCREEN‐Japan 01},
  journal = {Cancer Science},
  year = {2023},
  doi = {10.1111/cas.15746}
}
Kostenlos starten →